Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Exp Cell Res. 2017 Apr 19;356(1):93–103. doi: 10.1016/j.yexcr.2017.04.016

Figure 5. STAT3 inhibitors attenuate cell viability and EGFR activity in MDA-MB-468 cells.

Figure 5

MDA-MB-468 cells, plated and treated in parallel, were assessed for cell viability using an Alamar Blue assay. Data from A. Stattic or C. S31-201 treated cells are expressed as the average ± SEM (n=3) relative to cells treated without serum (SF). Serum-starved cells were pre-treated for 1 hour with 0 (0.025% DMSO), 0.3, 1, 3, 5, or 10 μM Stattic (IC50 = 5.1 μM; panel B.), or with 0 (0.5% DMSO), 1, 3, 10, 30, and 100 μM S3I-201(IC50 = 86 μM; panel D.), followed by the addition of 16 nM EGF (+) for 24 hours. Control cells were incubated with serum free media alone (SF), media containing 10% fetal bovine serum (FBS), or 16 nM EGF (EGF) for 24 hours. As a positive control cells were treated with 1 μM staurosporine (STS) for 4 hours. Cell lysates were prepared and 40 μg were resolved by SDS-PAGE before being assessed for the indicated proteins. For STS treated samples, 15 μg of cell lysates were loaded to keep the signals in the dynamic range. Shown is a representative experimental replicate of three.